Corvus Pharmaceuticals unveils updated data from Phase 1/1b trial
Category: #health  By Saipriya Iyer  Date: 2020-02-03
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Corvus Pharmaceuticals unveils updated data from Phase 1/1b trial

Corvus Pharmaceuticals, Inc., a clinical-stage science driven biopharmaceutical firm focusing on the commercialization and development of precisely targeted oncology therapies along with biomarker patient enrichment selection, has reportedly announced updated results from its Phase 1/1b clinical-stage trial of CPI-818, the ITK inhibitor of the company, presented in an oral presentation during the 12th edition of Annual T-Cell Lymphoma Forum 2020, held in La Jolla, California.

Chief Medical Officer, Corvus, Mehrdad Mobasher, M.D., stated that the Phase 1/1b clinical-stage trial of CPI-818, company’s covalent ITK inhibitor which is designed to address T-cell lymphomas, has been well enrolled and continues to offer promising clinical data for patients suffering from advanced, obstinate forms of this cancer.

Mobasher further stated that till date, the data shows that the pharmacology and biology of ITK inhibition with CPI-818 has been expected and is proceeding according to the plan. The company is thrilled to provide updated data at the T-cell Lymphoma Forum, a meeting specifically devoted to this difficult to treat cancer family. The company is now ready to proceed the trial to higher doses of drug where the company would evaluate the activity in specific disease groups.

The Phase 1/1b trial of CPI-818 study is presently enrolling patients with various types of progressive, refractory T-cell lymphomas, which includes AITL (angioimmunoblastic T-cell lymphoma), PTCL-NOS (peripheral T-cell lymphoma-not otherwise specified), CTCL (cutaneous T-cell lymphoma), as well as other T-cell lymphomas. The study utilizes an adaptive, extended cohort design to evaluate the safety, select the dose, target occupancy, biomarkers, PK (pharmacokinetics), and effectiveness of CPI-818.

The primary phase of the trial has been evaluating increasing doses in successive groups of patients so as to ascertain the optimum dose. The second phase is likely to evaluate tumor and safety response to this ideal dose of CPI-818 in patients with disease specific cohorts that might be extended based on early signs of potency. The study is also enrolling patients at key medical centers located in Australia, South Korea, and the United States.

Source credit: https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-updated-clinical-data-its-phase



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...